-
公开(公告)号:US20120035408A1
公开(公告)日:2012-02-09
申请号:US13106337
申请日:2011-05-12
申请人: Jean-Damien Charrier , Steven John Durrant , Stephen Clinton Young , Pierre-Henri Storck , Anisa Nizarali Virani , Phillip Michael Reaper , Joanne Pinder
发明人: Jean-Damien Charrier , Steven John Durrant , Stephen Clinton Young , Pierre-Henri Storck , Anisa Nizarali Virani , Phillip Michael Reaper , Joanne Pinder
IPC分类号: A61N5/00 , A61K31/4965 , A61P35/00 , A61K31/497 , C07D401/04 , C07D241/20 , C07D403/04
CPC分类号: C07D241/20 , C07D401/04 , C07D403/04
摘要: The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula V: wherein the variables are as defined herein.
摘要翻译: 本发明涉及可用作ATR蛋白激酶抑制剂的吡嗪和吡啶化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病,病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法,如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式V:其中变量如本文所定义。